Here's what you need to know about the four CFTR (cystic fibrosis transmembrane conductance regulator) modulators.
Kalydeco Marks the Latest Success of the Cystic Fibrosis Foundation’s Venture Philanthropy Model
CF Foundation Provided Scientific, Clinical and Significant Funding Support in Drug Development Process
This medicine represents the single greatest therapeutic advancement in the history of CF, offering a treatment for the underlying cause of the disease that could eventually benefit more than 90 percent of people with CF.
Drug Targets the Underlying Cause of the Disease in People with the Most Common CF Mutation